| Inhibiting MEK in MAPK pathway-activated myeloma CJ Heuck, Y Jethava, R Khan, F van Rhee, M Zangari, S Chavan, ... Leukemia 30 (4), 976-980, 2016 | 109 | 2016 |
| Update on the optimal use of bortezomib in the treatment of multiple myeloma M Mohan, A Matin, FE Davies Cancer management and research, 51-63, 2017 | 71 | 2017 |
| Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease M Mohan, A Buros, P Mathur, N Gokden, M Singh, S Susanibar, ... American Journal of Hematology 92 (8), 739-745, 2017 | 50 | 2017 |
| Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome M Mohan, N Weinhold, C Schinke, S Thanedrarajan, L Rasche, ... British Journal of Haematology 189 (1), 67-71, 2020 | 43 | 2020 |
| Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients MB Abid, M Rubin, N Ledeboer, A Szabo, W Longo, M Mohan, NN Shah, ... Cancer Cell 40 (4), 340-342, 2022 | 38 | 2022 |
| Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns C Schinke, EM Boyle, C Ashby, Y Wang, V Lyzogubov, C Wardell, P Qu, ... Blood cancer journal 10 (6), 70, 2020 | 33 | 2020 |
| Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma M Mohan, S Nagavally, B Dhakal, SV Radhakrishnan, S Chhabra, ... Blood Advances 6 (8), 2466-2470, 2022 | 28 | 2022 |
| The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype C Schinke, A Hoering, H Wang, V Carlton, S Thanandrarajan, ... Haematologica 102 (8), e313, 2017 | 28 | 2017 |
| Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study J Dong, Z Garacci, CS Buradagunta, A D’Souza, M Mohan, ... Blood Cancer Journal 12 (2), 34, 2022 | 26 | 2022 |
| Salvage second transplantation in relapsed multiple myeloma B Dhakal, A D’Souza, A Kleman, S Chhabra, M Mohan, P Hari Leukemia 35 (4), 1214-1217, 2021 | 20 | 2021 |
| Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma M Mohan, S Kendrick, A Szabo, N Yarlagadda, D Atwal, Y Pandey, A Roy, ... Blood Advances 6 (3), 808-817, 2022 | 19 | 2022 |
| Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy S Al Hadidi, A Szabo, J Esselmann, L Hammons, M Hussain, ... Bone Marrow Transplantation 58 (4), 443-445, 2023 | 16 | 2023 |
| Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma LR Hammons, A Szabo, A Janardan, B Dhakal, S Chhabra, A D’Souza, ... JAMA Network Open 5 (10), e2238961-e2238961, 2022 | 16 | 2022 |
| Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma M Mohan, R Chakraborty, S Bal, A Nellore, M Baljevic, A D'Souza, ... British Journal of Haematology 203 (5), 736-746, 2023 | 15 | 2023 |
| Immunotherapy in multiple myeloma—Time for a second major paradigm shift M Mohan, P Hari, B Dhakal JCO Oncology Practice 17 (7), 405-413, 2021 | 15 | 2021 |
| Belantamab in combination with dexamethasone in patients with triple-class relapsed/refractory multiple myeloma T Atieh, S Atrash, M Mohan, L Shune, Z Mahmoudjafari, J Quick, J Riffel, ... Blood 138, 1642, 2021 | 13 | 2021 |
| Two Cases of Vancomycin-Resistant Enterococcus faecium Bacteremia With Development of Daptomycin-Resistant Phenotype and its Detection Using Oxford … Z Udaondo, P Jenjaroenpun, T Wongsurawat, E Meyers, C Anderson, ... Open Forum Infectious Diseases 7 (6), ofaa180, 2020 | 13 | 2020 |
| Salvage autologous stem cell transplantation in daratumumab-refractory multiple myeloma L Yarlagadda, S Gundarlapalli, R Parikh, RD Landes, M Kottarathara, ... Cancers 13 (16), 4019, 2021 | 12 | 2021 |
| Extensive remineralization of large pelvic lytic lesions following total therapy treatment in patients with multiple myeloma M Mohan, RS Samant, D Yoon, AF Buros, A Branca, CO Montgomery, ... Journal of Bone and Mineral Research 32 (6), 1261-1266, 2017 | 12 | 2017 |
| Daratumumab single agent and daratumumab plus pomalidomide and dexametasone in relapsed/refractory multiple myeloma: a real life retrospective evaluation A Branca, A Buros, D Yoon, LJ Suva, N Weinhold, L Rasche, C Schinke, ... Blood 128 (22), 4516, 2016 | 12 | 2016 |
